Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Patent number: 7090844Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: September 10, 2003Date of Patent: August 15, 2006Assignee: Abgenix, Inc.Inventors: Menashe Bar-Eli, Larry L. Green
-
Patent number: 7074405Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: June 22, 1999Date of Patent: July 11, 2006Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 7067131Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: December 26, 2002Date of Patent: June 27, 2006Assignee: Abgenix, Inc.Inventors: Jean Gudas, Larry L. Green, Menashe Bar-Eli
-
Patent number: 7063844Abstract: Provided are CD-1 presented antigens, compositions, cells, inhibitors and methods relating to the use of hydrophobic antigen presentation by CD1 molecules, including: methods for detecting the presence of a CD1-presented hydrophobic antigen in a sample; methods for isolating such CD1-presented antigens and isolated antigens; vaccines containing CD1-presented antigens and vaccination methods; methods of blocking CD1 antigen presentation; methods of identifying and/or isolating CD1 blocking agents and the isolated CD1 blocking agents; methods of inducing CD1 expression; and T-cells for use in the methods disclosed herein.Type: GrantFiled: May 21, 2001Date of Patent: June 20, 2006Assignee: The Brigham and Women's Hospital, Inc.Inventors: Steven A. Porcelli, Michael B. Brenner, Evan M. Beckman, Stephen T. Furlong
-
Patent number: 7060269Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: GrantFiled: November 27, 2000Date of Patent: June 13, 2006Assignee: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
-
Patent number: 7045129Abstract: A humanized chimera antibody, a pharmaceutical composition comprising a humanized chimera antibody and a pharmaceutically acceptable carrier, and a method of treating cancer which comprises administering to a patient a pharmaceutically acceptable amount of the humanized chimera antibody, are disclosed.Type: GrantFiled: June 12, 2002Date of Patent: May 16, 2006Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Mamoru Hasegawa, Hiromasa Miyaji, Yoshihisa Kuwana
-
Patent number: 7045605Abstract: Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or antigen-binding fragments thereof, have been rendered less immunogenic compared to their unmodified counterparts to a given species, e.g., a human. Pharmaceutical compositions including the aforesaid antibodies, nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments are also disclosed. Methods of using the antibodies of the invention to detect human PSMA, or to ablate or kill a PSMA-expressing cell, e.g., a PSMA-expressing cancer or prostatic cell, either in vitro or in vivo, are also provided.Type: GrantFiled: May 30, 2002Date of Patent: May 16, 2006Assignee: Cornell Research Foundation, Inc.Inventors: Neil Bander, Francis J. Carr, Anita Hamilton
-
Patent number: 7041634Abstract: This invention provides a method of inhibiting viable cells transplanted into a subject from being destroyed by the subject's immune system which comprises: a) containing the viable cells, or tissue comprising the viable cells, prior to transplantation within a device comprising a semipermeable membrane; and b) treating the subject with a substance which inhibits an immune-system costimulation event in an amount effective to inhibit the subject's immune system from responding to said contained cells or tissue. In one embodiment, the substance which inhibits an immune-system costimulation event is CTLA4.Type: GrantFiled: March 27, 1998Date of Patent: May 9, 2006Assignees: Emory University, Bristol Myers-Squibb CompanyInventors: Collin J. Weber, Mary K. Hagler, Peter S. Linsley, Judith A. Kapp, Susan A. Safley
-
Patent number: 7037498Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.Type: GrantFiled: January 4, 2002Date of Patent: May 2, 2006Assignees: Abgenix, Inc., Pfizer IncInventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
-
Patent number: 7029676Abstract: The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.Type: GrantFiled: June 7, 2002Date of Patent: April 18, 2006Assignee: The Brigham and Women's Hospital, Inc.Inventors: Michael B. Brenner, Karyn L. Cepek
-
Patent number: 7025962Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: April 10, 2000Date of Patent: April 11, 2006Assignee: Schering CorporationInventors: Daniel M. Gorman, Troy D. Randall, Albert Zlotnik
-
Patent number: 7022820Abstract: The present invention relates, in general, to a cancer-related protein and to a nucleic acid sequence encoding same. In particular, the invention relates to a protein over expressed in certain neoplastic cells, including breast and ovarian cancer cells, to its encoding sequence, and to diagnostic and treatment methodologies based on same.Type: GrantFiled: February 25, 2002Date of Patent: April 4, 2006Assignee: Duke UniversityInventors: Russel E. Kaufman, Kimberly Slentz-Kesler
-
Patent number: 7015312Abstract: The present invention discloses that the normal melanogenic gene, gp75 gene, encodes a gene product, a 24 amino acid peptide of ORF3, which is processed to an antigenic cancer peptide recognized by T lymphocytes. The cancer peptide of the invention derived from ORF3 is recognized by cancer antigen specific T lymphocytes as a tumor rejection antigen. The products of this gene are promising candidates for immunotherapeutic strategies for the treatment and diagnosis of patients with cancer.Type: GrantFiled: May 16, 2000Date of Patent: March 21, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rong-Fu Wang, Steven A. Rosenberg
-
Patent number: 6994853Abstract: The invention relates to the time-staggered utilization of tumor cells in combination with intact, preferably heterologous antibodies for the immunization of humans and animals.Type: GrantFiled: September 22, 1999Date of Patent: February 7, 2006Assignee: Trion Pharma GmbHInventors: Horst Lindhofer, Peter Ruf
-
Patent number: 6972324Abstract: The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said antibody proteins. The invention furthermore pertains to methods for producing said antibody proteins. The invention also provides pharmaceutical compositions comprising said antibody proteins. The invention furthermore is concerned with the use in the manufacture of a medicament for the treatment of cancer.Type: GrantFiled: May 20, 2002Date of Patent: December 6, 2005Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International, GmbHInventors: Günther Adolf, Elinborg Ostermann, Erik Patzelt, Marlies Sproll, Karl-Heinz Heider, John J. Miglietta, Augustinus Antonius Maria Silvester Van Dongen
-
Patent number: 6962702Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic linker is conjugated to one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them.Type: GrantFiled: April 3, 2001Date of Patent: November 8, 2005Assignee: Immunomedics Inc.Inventors: Hans J. Hansen, Gary L. Griffiths, Shui-on Leung, William J. McBride, Zhengxing Qu
-
Patent number: 6924360Abstract: The present invention relates generally to the generation and characterization of anti-MUC18 monoclonal antibodies. The invention further relates to the use of such anti-MUC18 antibodies in the diagnosis and treatment of disorders associated with increased activity of MUC18, in particular, tumors, such as melanomas.Type: GrantFiled: December 26, 2002Date of Patent: August 2, 2005Assignee: Abgenix, Inc.Inventors: Larry L. Green, Menashe Bar-Eli
-
Patent number: 6896885Abstract: The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN® (rituximab).Type: GrantFiled: April 2, 2001Date of Patent: May 24, 2005Assignee: Biogen Idec Inc.Inventor: Nabil Hanna
-
Patent number: 6891023Abstract: Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma deposited with the ECCC 97061101. The recombinant antibodies were obtained using recombinant DNA technology and are characterized in that they recognize antigen ior C2. The recombinant antibodies are specifically chimeric antibody, humanized antibody, and single chain Fv fragment. The chimeric antibody contains the variable domains of the murine immunoglobuline and the constant regions of the human immunoglobuline. The humanized antibody contains the constant regions of human immunoglobuline and has been specifically modified in the murine frameworks regions (FRs) and within the latter, in those areas that may result in an antigenic site for cells T. The Fv fragment contains the variable domains of murine immunoglobuline. The invention also relates to the utilization of recombinant antibodies derived from murine antibody ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof and recurrences.Type: GrantFiled: November 16, 2000Date of Patent: May 10, 2005Assignee: Centro Inmunologia MolecularInventors: Cristina Maria Mateo de Acosta Del Rio, Lourdes Tatiana Roque Navarro, Alejo Morales Morales, Rolando Pérez Rodríguez, Marta Ayala Ávila, Jorge Victor Gavilondo Cowley, Marta Dueñas Porto, Hanssel Bell García, Enrique Rengifo Calzado, Normando Iznaga Escobar, Mayra Ramos Zuzarte
-
Patent number: 6884417Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: May 15, 2001Date of Patent: April 26, 2005Assignee: The Scripps Research InstituteInventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
-
Patent number: 6846807Abstract: Development of colorectal neoplasia in a patient subject or predisposed to colorectal neoplasia is reduced by the steps of (a) determining a patient is subject or predisposed to colorectal neoplasia; and (b) enterically delivering into the gut of the person an effective amount of an aminoglycoside antibiotic having poor gut absorption, whereby the development of the colorectal neoplasia is reduced as compared with otherwise similar non-treated patients.Type: GrantFiled: July 25, 2003Date of Patent: January 25, 2005Assignee: Board of Regents, The University of Texas SystemInventors: Jonathan Graff, Matthew Wieduwilt
-
Patent number: 6824780Abstract: The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.Type: GrantFiled: October 27, 2000Date of Patent: November 30, 2004Assignee: Genentech, Inc.Inventors: Brigitte Devaux, Gilbert-Andre Keller, Hartmut Koeppen, Lawrence A. Lasky
-
Patent number: 6803035Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.Type: GrantFiled: January 22, 2002Date of Patent: October 12, 2004Assignee: Arkion Life SciencesInventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
-
Patent number: 6767541Abstract: The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods for inhibiting the growth of cancer cells that exhibit certain genetic profiles. These methods identify an important link between HER-2/neu overexpression and loss of growth inhibition by the TGF-&bgr; signaling pathway in cancer cells. Compositions as well as therapeutic and diagnostic methodologies based on this disclosure are provided.Type: GrantFiled: March 20, 2001Date of Patent: July 27, 2004Assignees: The Regents of the University of California, Amgen Inc.Inventors: Dennis J. Slamon, Cindy A. Wilson, Frank J. Calzone
-
Patent number: 6759043Abstract: It is the objective and purpose of the present invention to provide a monoclonal antibody having the property of causing apoptosis on myeloid cells. This invention relates to a monoclonal antibody having the property of causing apoptosis on myeloid cells, and fragments thereof, and furthermore relates to a hybridoma producing the monoclonal antibody. Since the monoclonal antibodies of the present invention are useful as antibodies recognizing and identifying antigens causing apoptosis on myeloid cells specifically and besides have the property of causing apoptosis on myeloid cells, they may be used as medicine useful in the field of remedies for myelocytic leukemia utilizing the property.Type: GrantFiled: December 15, 2000Date of Patent: July 6, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventor: Naoshi Fukushima
-
Patent number: 6756036Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.Type: GrantFiled: September 26, 2001Date of Patent: June 29, 2004Assignees: Regents of the University of California, Agensys, Inc.Inventors: Robert E. Reiter, Owen N. Witte
-
Patent number: 6743430Abstract: Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant.Type: GrantFiled: March 29, 1995Date of Patent: June 1, 2004Inventors: Richard E. Parizek, Lonny E. Vlieger, Sharon A. Bryant, Stuart K. Nibbelink, Michael J. McGinley
-
Patent number: 6733752Abstract: Prevention of transformation of a normal cell into a tumour cell in an individual at risk of developing a tumour having tumours which have p185 on their surfaces comprises: (a) identifying the individual and (b) administering to the individual an antibody which specifically binds to p185. Also claimed is a method of preventing transformation of a normal cell into a tumour cell that has p185 on its surface in an individual who has had a tumour that has p185 on its cell surfaces removed or who has had a cancer characterised by tumour cells that have p185 on their surfaces enter remission, comprising (a) identifying the individual and (b) administering to the individual an antibody which specifically binds to p185.Type: GrantFiled: November 20, 1995Date of Patent: May 11, 2004Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Makoto Katsumato
-
Patent number: 6727349Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: February 3, 2000Date of Patent: April 27, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 6703020Abstract: Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate and prodrug compositions.Type: GrantFiled: April 28, 2000Date of Patent: March 9, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Rolf A. Brekken
-
Patent number: 6703488Abstract: A method for intracellular delivery of drugs or other agents for diagnosis and therapy of malignancies or immune-mediated or inflammatory conditions. A targeting moiety of an antibody and the ligand-binding region of a selected cytokine receptor is used. The targeting moiety targets surface antigen on a specific cell population. The targeting moiety is administered to a subject, and then, after a specified interval, therapeutic or diagnostic agents linked to the cognate cytokine are given. The invention provides rapid, efficient internalization of the cytokine receptor antibody/antigen complexes. Targeting of a high-level cell surface antigen with such bispecific fusion molecules substantially increases the number of cytokine receptors over their low background level.Type: GrantFiled: January 15, 1999Date of Patent: March 9, 2004Assignee: Center for Molecular Medicine and ImmunologyInventors: Jack D. Burton, David M. Goldenberg
-
Patent number: 6703489Abstract: The present invention relates to nucleotide sequences of Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. Methods of production of the Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.Type: GrantFiled: November 19, 1998Date of Patent: March 9, 2004Assignees: Yale University, Imperial Cancer Research Technology, Ltd.Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Anna Mary Myat, Robert J. Fleming, Spyridon Artavanis-Tsakonas, Robert S. Mann, Grace E. Gray
-
Patent number: 6699974Abstract: A reshaped human anti-HM 1.24 antibody comprising: (A) an L chain comprising (1) the C region of a human L chain, and (2) the V region of an L chain comprising the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1.24 monoclonal antibody; and (B) an H chain comprising (1) the C region of a human H chain, and (2) the V region of an H chain comprising the FR of a human H chain and the CDR of the H chain of a mouse anti-HM 1.24 monoclonal antibody. Since most of this reshaped human antibody is derived from human antibody and the CDR has a low antigenicity, the reshaped human antibody of the present invention has a low antigenicity and, therefore, is expected to be-used for medical treatment.Type: GrantFiled: April 1, 1999Date of Patent: March 2, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Koichiro Ono, Toshihiko Ohtomo, Masayuki Tsuchiya, Yasushi Yoshimura, Yasuo Koishihara, Masaaki Kosaka
-
Patent number: 6696550Abstract: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.Type: GrantFiled: April 23, 2001Date of Patent: February 24, 2004Assignee: Millennium Pharmaceuticals, Inc.Inventors: Gregory J. LaRosa, Christopher Horvath, Walter Newman, S. Tarran Jones, Siobhan H. O'Brien, Theresa O'Keefe
-
Patent number: 6682734Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.Type: GrantFiled: June 7, 1995Date of Patent: January 27, 2004Assignee: IDEC Pharmaceuticals CorporationInventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 6676940Abstract: The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.Type: GrantFiled: July 24, 2001Date of Patent: January 13, 2004Assignee: The Scripps Research InstituteInventors: Dario C. Altieri, Lucia R. Languino, George B. Thornton
-
Patent number: 6669938Abstract: Immunoconjugates of an antibody to a 22 KD breast tumor associated antigen were prepared. Cytotoxic immunoconjugates such as gelonin-15A8 antibody conjugate are useful for treating proliferative cell diseases such as breast carcinoma and cervical carcinoma as well as other tumors which bear the 15A8 antigen. Detectably labeled compositions for diagnosis of such diseases are also disclosed.Type: GrantFiled: September 24, 1993Date of Patent: December 30, 2003Assignee: Research Development FoundationInventors: Michael G. Rosenblum, Renato Dulbecco, W. Ross Allen
-
Patent number: 6656465Abstract: The use and production of immunoglobulins which activate trk receptors and imitate effects of neurotrophins are provided. Immunoglobulins which block trk receptor activation and methods of use are also provided.Type: GrantFiled: January 26, 2001Date of Patent: December 2, 2003Assignee: The Regents of the University of CaliforniaInventors: Douglas O. Clary, Gisela Weskamp, Leeann R. Austin, Louis F. Reichardt
-
Patent number: 6652853Abstract: This invention relates to a combination of immunotherapy and chemotherapy to promote tumor regression by treating a patient in need thereof with a combination of a humanized antibody that binds to A33 antigen and one or more chemotherapeutic agents. The method is useful for treating patients with colorectal cancer and gastric carcinomas. The method is particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.Type: GrantFiled: March 8, 2001Date of Patent: November 25, 2003Assignees: Ludwig Institute for Cancer Research, Sloan Kettering Institute for Cancer ResearchInventors: Sydney Welt, Nancy Kemeny, Gerd Ritter, Achim A. Jungbluth, Leonard Cohen, Lloyd J. Old
-
Patent number: 6630584Abstract: More than 90% of mutations found in the p53 protein produce a conformational change in p53 which results in the exposure of an epitope, which is otherwise hidden in the hydrophobic core of the molecule. A single chain antibody (scFv) which specifically recognizes this common mutant epitope in mutant p53 but not in wild type p53 is disclosed. Also described are a DNA molecule encoding the scFv, pharmaceutical compositions comprising the antibody and methods of treatment using the pharmaceutical compositions.Type: GrantFiled: March 16, 2000Date of Patent: October 7, 2003Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Beka Solomon, Gerald Cohen, Dimitri Govorko
-
Patent number: 6627196Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.Type: GrantFiled: August 25, 2000Date of Patent: September 30, 2003Assignee: Genentech, Inc.Inventors: Sharon A. Baughman, Steven Shak
-
Publication number: 20030157093Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.Type: ApplicationFiled: September 3, 1999Publication date: August 21, 2003Inventors: DAVID M. NEVILLE, JR., JOSHUA E. SCHARFF, JERRY TODD THOMPSON, HUAIZHONG HU, SHENGLIN MA
-
Publication number: 20030113334Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity.Type: ApplicationFiled: December 10, 2002Publication date: June 19, 2003Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Yasuo Koishihara, Yasushi Yoshimura
-
Patent number: 6569430Abstract: An antibody is produced, which will bind effectively with the antigen Campath-1, and which has at least one complementarity determining region of rat origin, as identified in FIG. 2, which may be combined with a range of different foreign variable domain framework regions as desired, including framework regions of human origin.Type: GrantFiled: March 21, 1995Date of Patent: May 27, 2003Assignee: BTG International LimitedInventors: Herman Waldmann, Michael R. Clark, Gregory P. Winter, Lutz Riechmann
-
Publication number: 20030073613Abstract: An isolated polypeptide having at least 80% sequence identity to the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14 or 16, and polynucleotides encoding the same, are useful for modulating angiogenesis.Type: ApplicationFiled: March 22, 2001Publication date: April 17, 2003Inventors: Mary Gerritsen, Luca Rastelli
-
Publication number: 20030045691Abstract: A reshaped human anti-HM 1.Type: ApplicationFiled: April 1, 1999Publication date: March 6, 2003Inventors: KOICHIRO ONO, TOSHIHIKO OHTOMO, MASAYUKI TSUCHIYA, YASUSHI YOSHIMURA, YASUO KOISHIHARA
-
Patent number: 6509016Abstract: The present invention relates to monoclonal antibody 1A7. This is an anti-idiotype produced by immunizing with an antibody specific for ganglioside GD2, and identifying a hybridoma secreting antibody with immunogenic potential in a multi-step screening process. Also disclosed are polynucleotide and polypeptide derivatives based on 1A7, including single chain variable region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 1A7 antibody overcomes immune tolerance and induces an immune response against GD2, which comprises a combination of anti-GD2 antibody and GD2-specific T cells. The invention further provides methods for treating a disease associated with altered GD2 expression, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma. Patients who are in remission as a result of traditional modes of cancer therapy may be treated with a composition of this invention in hopes of reducing the risk of recurrence.Type: GrantFiled: April 15, 1999Date of Patent: January 21, 2003Assignee: The Board of Trustees of the University of KentuckyInventors: Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee
-
Patent number: 6503510Abstract: A therapeutic agent for lymphatic tumors (excluding myeloma) comprising as an active ingredient an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO:1 and SEQ ID NO:5 and that has a cytotoxic activity.Type: GrantFiled: August 11, 1999Date of Patent: January 7, 2003Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasuo Koishihara, Yasushi Yoshimura
-
Publication number: 20020192724Abstract: The present invention relates to methods and compositions for modulating the heterotypic adhesion between E-cadherin expressing cells and T lymphocytes. Monoclonal antibodies which specifically bind to E-cadherin and isolated peptides which mimic the binding function of E-cadherin also are provided. The antibodies and peptides are useful in screening assays to identify pharmaceutical lead compounds which are capable of modulating adhesion between T lymphocytes and E-cadherin expressing cells. Methods and pharmaceutical compositions for modifying the mucosal immune response of a subject also are provided.Type: ApplicationFiled: June 7, 2002Publication date: December 19, 2002Inventors: Michael B. Brenner, Karyn L. Cepek
-
Patent number: 6495137Abstract: Novel composite and humanized anti-TAG-72 monoclonal antibodies, antibody fragments, and derivatives thereof using human subgroup IV kappa light chain framework regions.Type: GrantFiled: October 30, 1997Date of Patent: December 17, 2002Assignee: The Dow Chemical CompanyInventors: Peter S. Mezes, Ruth A. Richard, Kimberly S. Johnson, Jeffrey Schlom, Syed V. S. Kashmiri, Liming Shu, Eduardo A. Padlan